Filing Flows

Filing Flows › Aurinia Pharmaceuticals (AUPH) › Next earnings date

Aurinia Pharmaceuticals (AUPH) earnings: beat the estimate

Aurinia Pharmaceuticals (AUPH) reported on Oct 30, 2026 and beat the EPS estimate: $0.23 against $0.22 (+4.5%). Revenue was $83.7M for Q3 2026, +14% year over year. The stock moved -6.2% on the report. It beat the EPS estimate in 100% of the quarters on record.

Last result+4.5% vs estimate
Beat rate100%

The last report

Aurinia Pharmaceuticals reported revenue of $83.7M for the third quarter 2026 (+14% Y/Y), net earnings $31.7M: Net product sales $79.4M, License, collaboration and royalty revenue $4.3M. How it makes money → · Every quarter →

Aurinia Pharmaceuticals: EPS against the estimate, last 5 reportsAurinia Pharmaceuticals: EPS against the estimate, last 5 reportsEstimateReported$0.16$0.23Nov 25$0.22$1.53Feb 26$0.20$0.25May 26$0.24$0.28Aug 26$0.22$0.23Oct 26
Latest (Oct 26): Estimate $0.22, Reported $0.23.
AUPH: the stock's move on each reportAUPH: the stock's move on each reportOct 30, 2026-6.2%Aug 6, 2026+4.3%May 7, 2026-6.2%Feb 26, 2026-1.8%Nov 4, 2025+9.7%

Aurinia Pharmaceuticals' latest quarter

Aurinia Pharmaceuticals, Q3 2026: revenue $83.7M (+14% year over year), operating margin 42.3%, net earnings $31.7M, operating cash flow $46.4M. The chart follows the revenue to costs, profit and cash.

Questions

Did Aurinia Pharmaceuticals beat earnings?

Aurinia Pharmaceuticals (AUPH) reported on Oct 30, 2026 and beat the EPS estimate: $0.23 against $0.22 (+4.5%).

When does AUPH report earnings?

The next date is not set yet.

Does Aurinia Pharmaceuticals usually beat earnings?

It beat the consensus EPS estimate in 100% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.